Tumor Biology

, Volume 37, Issue 2, pp 2587–2596 | Cite as

The role of Kaposi’s sarcoma-associated herpesvirus infection in the proliferation of human bladder cancer cells

Original Article

Abstract

Existing evidence suggests a possible role of viruses in human bladder cancer development. Recently, Kaposi’s sarcoma-associated herpesvirus (KSHV) was reported to be the most frequently detected virus in bladder cancer tissue from Croatian patients on screening with the Lawrence Livermore Microbial Detection Array. In the current study, to investigate the functional roles of KSHV in bladder cancer, five bladder cancer cell lines were infected with KSHV and their tumour progression-associated changes investigated. Four KSHV-infected bladder cancer cell lines were established; two invasive bladder cancer cell lines showed higher proliferation rates than uninfected cells. Additionally, these KSHV-infected invasive bladder cancer cells showed a greater number of colonies, which were also significantly larger than those of uninfected cells, in a soft agar colony formation assay. cDNA microarray analysis showed that various genes associated with cell proliferation and cancer development were upregulated in these KSHV-infected bladder cancer cells. Taken together, we suggest that KSHV infection affects the proliferation of a subset of invasive bladder cancer cells and may therefore play a role in their oncogenic progression. Further studies are required to elucidate the exact mechanism used by KSHV to promote bladder cancer progression.

Keywords

Bladder cancer Human herpesvirus 8 Kaposi’s sarcoma-associated herpesvirus Proliferation Microarray 

Notes

Acknowledgments

This work was supported by EMBRI Grant 2015-EMBRI-DJ0001 from the Eulji University.

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Yin WY, Lee MC, Lai NS, Lu MC. BK virus as a potential oncovirus for bladder cancer in a renal transplant patient. J Formos Med Assoc. 2015;114(4):373–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res. 2015;35(5):2513–9.PubMedGoogle Scholar
  5. 5.
    Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S. Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol. 2014;32(1):46 e19–27.CrossRefGoogle Scholar
  6. 6.
    Paradzik M, Bucevic-Popovic V, Situm M, Jaing CJ, Degoricija M, McLoughlin KS, et al. Association of Kaposi’s sarcoma-associated herpesvirus (KSHV) with bladder cancer in Croatian patients. Tumour Biol. 2014;35(1):567–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Ogawa S, Yasui T, Taguchi K, Umemoto Y, Kojima Y, Kohri K. The probability of involvement of human papillomavirus in the carcinogenesis of bladder small cell carcinoma, prostatic ductal adenocarcinoma, and penile squamous cell carcinoma: a case report. BMC Res Notes. 2014;7(1):909.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kim SH, Joung JY, Chung J, Park WS, Lee KH, Seo HK. Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation. PLoS One. 2014;9(3):e93525.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chawki S, Ploussard G, Montlahuc C, Verine J, Mongiat-Artus P, Desgrandchamps F, et al. Bladder cancer in HIV-infected adults: an emerging concern? J Int AIDS Soc. 2014;17(4 Suppl 3):19647.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Shigehara K, Kawaguchi S, Sasagawa T, Nakashima K, Nakashima T, Shimamura M, et al. Etiological correlation of human papillomavirus infection in the development of female bladder tumor. APMIS. 2013;121(12):1169–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, et al. Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study. Int J Cancer. 2013;133(3):597–603.CrossRefPubMedGoogle Scholar
  12. 12.
    Hemmaid KZ, Awadalla A, Elsawy E, Hussein A-AM, Abdel- Aziz A, Shokeir AA, et al. Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer. Infect Agents Cancer. 2013;8(1):24.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chapman-Fredricks JR, Cioffi-Lavina M, Accola MA, Rehrauer WM, Garcia-Buitrago MT, Gomez-Fernandez C, et al. High-risk human papillomavirus DNA detected in primary squamous cell carcinoma of urinary bladder. Arch Pathol Lab Med. 2013;137(8):1088–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Berrada N, Al-Bouzidi A, Ameur A, Abbar M, El-Mzibri M, Ameziane-El-Hassani R, et al. Human papillomavirus detection in Moroccan patients with bladder cancer. J Infect Dev Ctries. 2013;7(8):586–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Badawi H, Ahmed H, Aboul Fadl L, Helmi A, Fam N, Diab M, et al. Herpes simplex virus type-2 in Egyptian patients with bladder cancer or cystitis. APMIS. 2010;118(1):37–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Husain E, Prowse DM, Ktori E, Shaikh T, Yaqoob M, Junaid I, et al. Human papillomavirus is detected in transitional cell carcinoma arising in renal transplant recipients. Pathology. 2009;41(3):245–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Badawi H, Ahmed H, Ismail A, Diab M, Moubarak M, Badawy A, et al. Role of human papillomavirus types 16, 18, and 52 in recurrent cystitis and urinary bladder cancer among Egyptian patients. Medscape J Med. 2008;10(10):232.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Youshya S, Purdie K, Breuer J, Proby C, Sheaf MT, Oliver RT, et al. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol. 2005;58(2):207–10.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wiwanitkit V. Urinary bladder carcinoma and human papilloma virus infection, an appraisal of risk. Asian Pac J Cancer Prev. 2005;6(2):217–8.PubMedGoogle Scholar
  20. 20.
    Escudero AL, Luque RJ, Quintero A, Alvarez-Kindelan J, Requena MJ, Montironi R, et al. Association of human herpesvirus type 6 DNA with human bladder cancer. Cancer Lett. 2005;230(1):20–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis. 2005;5:102.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shigehara K, Sasagawa T, Namiki M. Human papillomavirus infection and pathogenesis in urothelial cells: a mini-review. J Infect Chemother. 2014;20(12):741–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Panagiotakis GI, Papadogianni D, Chatziioannou MN, Lasithiotaki I, Delakas D, Spandidos DA. Association of human herpes, papilloma and polyoma virus families with bladder cancer. Tumour Biol. 2013;34(1):71–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Schulz TF, Chang Y, et al. KSHV gene expression and regulation. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, editors. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007.Google Scholar
  25. 25.
    Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Schulz TF. KSHV (HHV8) infection. J Infect. 2000;41(2):125–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Jones T, Ye F, Bedolla R, Huang Y, Meng J, Qian L, et al. Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest. 2012;122(3):1076–81.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, et al. Construction and manipulation of a new Kaposi’s sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol. 2012;86(18):9708–20.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yoo SM, Ahn AK, Seo T, Hong HB, Chung MA, Jung SD, et al. Centrifugal enhancement of Kaposi’s sarcoma-associated virus infection of human endothelial cells in vitro. J Virol Methods. 2008;154(1–2):160–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest. 2010;120(4):939–49.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Boshoff C, Chang Y. Kaposi’s sarcoma-associated herpesvirus: a new DNA tumor virus. Annu Rev Med. 2001;52(1):453–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62(23):6973–80.PubMedGoogle Scholar
  33. 33.
    Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res. 1998;58(23):5348–53.PubMedGoogle Scholar
  34. 34.
    Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet. 1993;342(8869):469–71.CrossRefPubMedGoogle Scholar
  35. 35.
    Vallot C, Stransky N, Bernard-Pierrot I, Herault A, Zucman-Rossi J, Chapeaublanc E, et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst. 2011;103(1):47–60.CrossRefPubMedGoogle Scholar
  36. 36.
    Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al. The epidemiology of KSHV and its association with malignant disease. Cambridge: Cambridge University Press; 2007.Google Scholar
  37. 37.
    Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10(2):133–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, et al. Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell. 2003;3(2):131–43.CrossRefPubMedGoogle Scholar
  39. 39.
    Cavallin LE, Goldschmidt-Clermont P, Mesri EA. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. PLoS Pathog. 2014;10(7):e1004154.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Moody R, Zhu Y, Huang Y, Cui X, Jones T, Bedolla R, et al. KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog. 2013;9(12):e1003857.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Microbiology and ImmunologyEulji University School of MedicineJung-guSouth Korea
  2. 2.Department of UrologyEulji University Hospital, Eulji University School of MedicineSeo-guSouth Korea

Personalised recommendations